Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

GeneDx Holdings (WGS) Shares Outstanding (2020 - 2026)

GeneDx Holdings has reported Shares Outstanding over the past 7 years, most recently at $29.7 million for Q1 2026.

  • Quarterly Shares Outstanding rose 3.98% to $29.7 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $29.7 million through Mar 2026, up 3.98% year-over-year, with the annual reading at $29.2 million for FY2025, 4.39% up from the prior year.
  • Shares Outstanding was $29.7 million for Q1 2026 at GeneDx Holdings, up from $29.2 million in the prior quarter.
  • Over five years, Shares Outstanding peaked at $381.4 million in Q3 2022 and troughed at $7.4 million in Q1 2022.
  • The 5-year median for Shares Outstanding is $27.4 million (2024), against an average of $66.8 million.
  • Year-over-year, Shares Outstanding soared 258132.97% in 2022 and then tumbled 90.13% in 2023.
  • A 5-year view of Shares Outstanding shows it stood at $11.8 million in 2022, then soared by 120.66% to $26.0 million in 2023, then rose by 7.84% to $28.0 million in 2024, then grew by 4.39% to $29.2 million in 2025, then rose by 1.44% to $29.7 million in 2026.
  • Per Business Quant, the three most recent readings for WGS's Shares Outstanding are $29.7 million (Q1 2026), $29.2 million (Q4 2025), and $28.9 million (Q3 2025).